Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H16O6P2.2Na.2H |
| Molecular Weight | 330.1627 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[Na+].[Na+].[O-]P([O-])(=O)C(CC1CCCCCC1)P([O-])([O-])=O
InChI
InChIKey=RLIRIVMEKVNVQX-UHFFFAOYSA-L
InChI=1S/C9H20O6P2.2Na/c10-16(11,12)9(17(13,14)15)7-8-5-3-1-2-4-6-8;;/h8-9H,1-7H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2
Incadronate (Disodium Cycloheptylaminomethylene diphosphate) is used to treat malignancy-associated hypercalcemia (MAH) in Japan. Experiments on rodents have revealed that this drug could be an effective agent for the treatment of various arthritic conditions, including human rheumatoid arthritis. In addition was shown, that incadronate induced growth inhibition and apoptotic death of pancreatic cancer cells. Incadronate also inhibited migration presumably by preventing the activation of Rho by lysophosphatidic acid. Thus, this drug can be of value in regimens for the treatment of pancreatic cancer.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hydronium (cycloheptylammonio)methylene-1,1-bisphosphonate (hydronium incadronate). | 2003 Feb |
|
| Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis. | 2005 |
|
| The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis. | 2006 Jun |
|
| Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. | 2007 May |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000078559
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | |||
|
SUB16419MIG
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | |||
|
119188
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | |||
|
7L16W0096A
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | |||
|
DB06255
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | |||
|
138330-18-4
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | |||
|
m6239
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
C071542
Created by
admin on Sat Dec 16 04:17:13 GMT 2023 , Edited by admin on Sat Dec 16 04:17:13 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
